Modular Medical (MODD) Investor presentation summary

Market opportunity and unmet needs

• Only 20% of insulin-dependent diabetes patients use pumps, with 80% relying on multiple daily injections despite pumps offering better glycemic control and systemic cost savings of $10,000 per patient per year after device costs.

• The US addressable market for next-generation insulin pumps is estimated at $3 billion, with 1.2 million type 1 and 1.6 million type 2 diabetes patients on multiple daily injections considered 'almost pumpers.'

• Current pump adoption is limited by complexity, high cost, and lack of accessibility, especially among primary care patients and those without access to endocrinologists.

Product innovation and differentiation

• The new pump features a simple push-button bolus, 90-day reusable design, 3-day cartridge, no external controller, and no charging or battery replacement.

• Delivers insulin with precision micro-dosing, continuous delivery, and a full-sized 3ml reservoir, matching leading pumps in accuracy while reducing cost of goods by 50%.

• Utilizes low-power Bluetooth, NFC, and a mobile app for easy pairing and data connectivity.

• Patent-protected technology enables automated, high-volume manufacturing and aims to make pumps easier to learn, use, and afford.

Commercialization strategy and rollout

• Received FDA 510(k) clearance in April 2026, with first shipments in June and a multi-city rollout targeting five key US markets by October 2026.

• Initial launch focuses on high-volume endocrinologists and prescribers with high affinity for new brand adoption in MDI patients.

• Engaging with providers and gathering feedback, with a commercialization council and partnership with Inizio to support execution.

• Plans to expand access through commission-based distributors and targeted education for both endocrinologists and primary care physicians.